Macular Society

Prevent Blindness Declares Third Annual Geographic Atrophy Awareness Week as Dec. 4-10, 2023

Retrieved on: 
Thursday, November 30, 2023
Well, Research to Prevent Blindness, Eye, Associate, Macular Society, Research, Macular degeneration, Visual impairment, Retina, Clinical trial, Patient, Cleveland Clinic, Geographic atrophy, Social media, MBA, University, BrightFocus Foundation, AMD, Partnership, Fact, Greater Baltimore Medical Center, News, Paratriathlon, Education, Pharmaceutical industry, Management, MD, Ophthalmology

CHICAGO, Nov. 30, 2023 /PRNewswire/ -- Prevent Blindness, the nation's leading nonprofit eye health organization, is announcing the third annual Geographic Atrophy (GA) Awareness Week as Dec. 4-10, 2023. GA is a medical term that refers to later-stage cases of dry age-related macular degeneration (AMD). Macular degeneration is an eye condition that affects the macula of the retina. More than 8 million people in the world have GA, with an estimated 1 million in the United States, according to the Cleveland Clinic.

Key Points: 
  • Prevent Blindness provides free geographic atrophy educational resources for patients, care partners and healthcare professionals, including new Focus on Eye Health Expert series episode, Web resource, Fact Sheets and More
    CHICAGO, Nov. 30, 2023 /PRNewswire/ -- Prevent Blindness , the nation's leading nonprofit eye health organization, is announcing the third annual Geographic Atrophy (GA) Awareness Week as Dec. 4-10, 2023.
  • "By working closely with their eye doctors, people with geographic atrophy (GA) have hope to preserve their vision from the damaging effects of GA," said Jeff Todd, president and CEO of Prevent Blindness.
  • This year's GA Awareness Week is supported by funding from Apellis Pharmaceuticals, Inc. , and Iveric Bio , an Astellas Company.
  • Additionally, Prevent Blindness is participating in the first World Geographic Atrophy Day on Tuesday, Dec. 5, 2023.

ONL Therapeutics to Highlight New Data in Upcoming Scientific Presentations at the 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research

Retrieved on: 
Thursday, January 26, 2023
ANN, Treatment, Geographic atrophy, Retina, European Association for Vision and Eye Research, International Society, Convention center, Gold Coast Convention and Exhibition Centre, GA, AMD, Patient, Geography, Macular Society, ISER, Therapy, Pharmaceutical industry

ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research (ISER).

Key Points: 
  • ANN ARBOR, Mich., Jan. 26, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will share new clinical data on ONL1204 Ophthalmic Solution in the treatment of patients with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD) at the upcoming 46th Annual Macula Society Meeting and the XXVth Biennial Meeting of the International Society for Eye Research (ISER).
  • The Macular Society Meeting is scheduled for February 15-18, 2023, at the Fontainebleau in Miami, Florida, while the ISER Meeting will take place February 19-23, 2023, at the Gold Coast Convention and Exhibition Centre in Broadbeach, Queensland, Australia.
  • Details of the Macular Society Meeting presentation are as follows:
    Fas Inhibition with ONL1204 for the Treatment of Geographic Atrophy: First-Time Interim Results from a Phase 1 Open-Label Dose Escalation Study
    2:34 p.m. Eastern Standard Time on Friday, February 17, 2023
    Details of the ISER Meeting presentation are as follows:

FDA-approved contact lenses to slow myopia progression in children

Retrieved on: 
Tuesday, May 11, 2021
Vision, Ophthalmology, Health, Senses, Disability, Near-sightedness, Corrective lenses, Retinal detachment, Optometry, Contact lens, Eye disease, Macular Society

This number is increasing at an alarming rate, especially among school-age children.\nMyopic children have higher chances of developing high myopia (a severe form of myopia).

Key Points: 
  • This number is increasing at an alarming rate, especially among school-age children.\nMyopic children have higher chances of developing high myopia (a severe form of myopia).
  • Patients with high myopia are prone to develop sight-threatening eye conditions such as cataracts, glaucoma, retinal detachment, and macular degeneration among other eye diseases.\nTo avoid sight-threatening eye conditions, myopia should be treated early.
  • Optometrists who practice myopic control can help curb kids\' myopia starting as early as age 7 and up.\n"MiSight multifocal contact lenses address the axial length, which is a core problem of myopia," says Dr.
  • "\nIntroducing myopic control at Eyepic Eye Care will help our communities understand the long-term effects of myopia and offer them a solution to slow its progression in children.

Global Macular Edema Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Health, Pharmaceutical, Ophthalmology, Macular edema, Clinical medicine, Medicine, Macula of retina, Anti–vascular endothelial growth factor therapy, Macular Society

b'The "Global Macular Edema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Macular Edema Epidemiology and Patient Flow Analysis - 2021, provides Macular Edema epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Macular Edema Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Macular Edema Epidemiology and Patient Flow Analysis - 2021, provides Macular Edema epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Macular Edema patients, history of the disease at the population level (Macular Edema prevalence, Macular Edema incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Macular Edema patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Macular Edema market sizing, assessing market potential, and developing drug forecast models\nIdentify Macular Edema patients segments through age groups, gender, and disease sub-types\nEvaluate Macular Edema market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005646/en/\n'

Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow to 2035: Focus on United States, Germany, France, Italy, Spain, UK, Japan, & G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 6, 2021
Health, Optical, Ophthalmology, Clinical medicine, Vision, Macular degeneration, Senescence, Macula of retina, Macular Society, Anti–vascular endothelial growth factor therapy

b'The "Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Wet Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Wet Age-Related Macular Degeneration epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Wet Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Wet Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Wet Age-Related Macular Degeneration epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Wet Age-Related Macular Degeneration patients, history of the disease at the population level (Wet Age-Related Macular Degeneration prevalence, Wet Age-Related Macular Degeneration incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nWet Age-Related Macular Degeneration patient flow: Wet Age-Related Macular Degeneration prevalence, diagnosed, and drug-treated patients\nDemographics: Wet Age-Related Macular Degeneration patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Wet Age-Related Macular Degeneration market sizing, assessing market potential, and developing drug forecast models\nIdentify Wet Age-Related Macular Degeneration patients segments through age groups, gender, and disease sub-types\nEvaluate Wet Age-Related Macular Degeneration market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210506005576/en/\n'

Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Report 2020-2035: Identify Patient Segments Through Age Groups, Gender, and Disease Sub-types - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 5, 2021
Health, Consumer, Practice Management, Seniors, Managed care, Optical, Ophthalmology, Organ systems, Vision, Macular degeneration, Senescence, Macula of retina, Macular Society, Macular edema

b'The "Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Dry Age-Related Macular Degeneration epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Dry Age-Related Macular Degeneration Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Dry Age-Related Macular Degeneration Epidemiology and Patient Flow Analysis - 2021, provides Dry Age-Related Macular Degeneration epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Dry Age-Related Macular Degeneration patients, history of the disease at the population level (Dry Age-Related Macular Degeneration prevalence, Dry Age-Related Macular Degeneration incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDry Age-Related Macular Degeneration patient flow: Dry Age-Related Macular Degeneration prevalence, diagnosed, and drug-treated patients\nDemographics: Dry Age-Related Macular Degeneration patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Dry Age-Related Macular Degeneration market sizing, assessing market potential, and developing drug forecast models\nIdentify Dry Age-Related Macular Degeneration patients segments through age groups, gender, and disease sub-types\nEvaluate Dry Age-Related Macular Degeneration market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210505005481/en/\n'

New Website for People Impacted by Age-Related Macular Degeneration Launched by Patient Advocacy Groups

Retrieved on: 
Thursday, March 25, 2021
Branches of biology, Ophthalmology, Macular degeneration, Senescence, Medicine, Emerging technologies, Blindness, AMD Alliance International, Macular Society

American Macular Degeneration Foundation is a non-profit organization committed to improving the lives of those affected by Age-related Macular Degeneration (AMD) through research, education, advocacy, and direct response to individuals requesting information.

Key Points: 
  • American Macular Degeneration Foundation is a non-profit organization committed to improving the lives of those affected by Age-related Macular Degeneration (AMD) through research, education, advocacy, and direct response to individuals requesting information.
  • BrightFocus Foundation is a non-profit organization funding exceptional scientific research worldwide to defeat macular degeneration, glaucoma and Alzheimer's disease, and provide expert information on these heartbreaking diseases.
  • MD Support is a world-wide non-profit public service organization that provides information and support for people who are affected by macular degeneration and similar retinal diseases.
  • AMD Central is an online resource that curates trusted information and support tools from leading patient advocacy organizations in one, convenient, accessible destination to help people with age-related macular degeneration (AMD) live their best lives.